Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
DMAC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.16
vs -0.13
Q3.23
N/A
-0.12
vs -0.12
Q4.23
N/A
-0.14
vs -0.14
Q1.24
N/A
-0.14
vs -0.20
Q2.24
N/A
-0.13
vs -0.16
Q3.24
N/A
-0.15
vs -0.12
Q4.24
N/A
-0.18
vs -0.14
Q1.25
N/A
-0.18
vs -0.14
Q2.25
N/A
-0.19
vs -0.13
Q3.25
N/A
-0.20
vs -0.15
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
-100%
NA vs 13K
Q3.23
-100%
NA vs 76K
Q4.23
NA
30.8M vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 30.8M
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
-7%
-0.07
vs -0.20
Q3.23
-8%
-0.08
vs -0.07
Q4.23
-10%
-0.10
vs -0.08
Q1.24
-11%
-0.11
vs -0.10
Q2.24
-10%
-0.10
vs -0.11
Q3.24
-13%
-0.13
vs -0.10
Q4.24
-19%
-0.19
vs -0.13
Q1.25
-23%
-0.23
vs -0.19
Institutionnal Ownership
QoQ
Q2.23
33
33
vs 26
27%
Q3.23
39
39
vs 33
18%
Q4.23
40
40
vs 39
3%
Q1.24
34
34
vs 40
-15%
Q2.24
34
34
vs 34
NA
Q3.24
42
42
vs 34
24%
Q4.24
47
47
vs 42
12%
Q1.25
60
60
vs 47
28%
businesswire.com
8 hours ago
seekingalpha.com
11 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
Forecast
NaN%2026-Revenue
-343%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
H.C. Wainwright
initialisePrevious: Not converted
2024-10-07
Now: Buy
Oppenheimer
upgradePrevious: Not converted
2023-06-22
Now: Outperform
Oppenheimer
upgradePrevious: Not converted
2023-06-22
Now: Hold
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
NASDAQ
Unprofitable
Unprofitable
0.06Â ( 1.71%)
Pre-market 3.80$0.23 (6.58%)
Relative Strenght
25
Volume Buzz
20%
Earning Acce
No
Dist 52w H.
48%Relative Strength
DMAC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|